Hindustan Bio Sciences Limited is an Indian enterprise primarily engaged in the **trading of drugs and medicines** and the **marketing of biotechnology products**. The company operates as a pure-play trading and marketing entity, maintaining a lean corporate structure with no direct involvement in manufacturing or technology development. ### Core Business Model and Operational Scope The company’s business model is centered on the procurement and distribution of pharmaceutical and biotech products. Because the company is exclusively engaged in trading, it operates under a **single business segment**, making segmental reporting non-applicable. * **Operational Focus:** Trading of Drugs & Medicines and marketing of specific biotechnology products. * **Technology Status:** No specific **technology absorption** or innovation has taken place as the company limits its scope to marketing activities. * **Energy Intensity:** Operations are **not energy intensive**. Conservation efforts are limited to administrative measures such as using energy-efficient monitors and heat-resistant materials in office spaces. * **Financial Facilities:** The company has **not availed any working capital facilities or term loans** from banks as of the most recent reporting period, indicating a debt-free status. ### Strategic Capital Restructuring and Solvency The company’s recent strategy has been defined by a significant **capital restructuring** exercise to address historical financial health and ensure a sustainable balance sheet. * **Capital Reduction Scheme:** Following an **NCLT Hyderabad Bench** order dated **January 6, 2023**, the company executed a restructuring under **Section 66** of the **Companies Act, 2013**. * Reduced the **Face Value** of **Equity Shares** from **Rs. 10/-** to **Rs. 2/-** per share. * Utilized **Rs. 8.20 Crore** from **Paid-up Share Capital** and **Rs. 8.20 Crore** from **Reserves** to write off **accumulated losses**. * **Solvency Status:** The company has confirmed that **no applications** for **Corporate Insolvency Resolution Process (CIRP)** have been filed by creditors or the company itself under the **Insolvency and Bankruptcy Code (IBC)**. * **Operational Stance:** The company maintains a conservative fiscal approach with **no active issuances** of sweat equity, employee stock options (ESOPs), or preferential allotments. ### Financial Performance and Turnaround Metrics The company has demonstrated a transition from significant **net losses** to consistent **profitability** over the last four fiscal years, despite a recent contraction in top-line revenue. | Fiscal Year | Total Revenue | Net Profit / (Loss) | Status | | :--- | :--- | :--- | :--- | | **FY 2024-25** | **Rs. 81.33 Lakhs** | **Rs. 10.07 Lakhs** | **Profit** | | **FY 2023-24** | **Rs. 1.05 Crore** | **Rs. 5.76 Lakhs** | **Profit** | | **FY 2022-23** | **Rs. 92.23 Lakhs** | **(Rs. 4.04 Lakhs)** | **Loss** | | **FY 2021-22** | **Rs. 43.06 Lakhs** | **(Rs. 51.75 Lakhs)** | **Loss** | **Key Financial Observations:** * **Profitability Trend:** The company achieved a **turnaround** in **FY 2023-24** and saw a **74.8% increase** in **Net Profit** during **FY 2024-25**, even as **Total Revenue** declined by approximately **22.5%** year-on-year. * **Reserves:** For the last three consecutive financial years, the company has not proposed any transfer of funds to the **General Reserves** account. ### Foreign Exchange and Export Dynamics Revenue is allocated geographically based on customer location. The company has consistently generated foreign exchange earnings through its trading activities, primarily through exports. | Particulars (Rs. in Lakhs) | 2024-25 | 2023-24 | 2022-23 | 2021-22 | | :--- | :---: | :---: | :---: | :---: | | **Foreign Exchange Earnings** | **81.11** | **99.39** | **58.70** | **41.75** | | **Foreign Exchange Outgo** | **0.00** | **0.00** | **0.00** | **24.86** | ### Capital Structure and Shareholding The company’s equity is almost entirely dematerialized, facilitating liquidity on Indian exchanges. * **Authorized Share Capital:** **Rs. 11,00,00,000** (5,50,00,000 equity shares of **Rs. 2/-** each). * **Paid-up Share Capital:** **Rs. 2,05,01,600** (1,02,50,800 equity shares of **Rs. 2/-** each). | Shareholding Mode | No. of Shares | % of Total Paid-up | | :--- | :--- | :--- | | **CDSL** | **4,902,321** | **47.82%** | | **NSDL** | **5,340,173** | **52.10%** | | **Physical** | **8,306** | **0.08%** | | **Total** | **10,250,800** | **100.00%** | ### Governance and Leadership Stability The company’s leadership is focused on maintaining a lean corporate structure while ensuring continuity in executive management. * **Leadership:** The board is led by **Sri J.V.R. Mohan Raju** (Chairman and Managing Director), who was re-appointed for a three-year term (**February 2024 to February 2027**). * **Key Appointments:** **Mr. Jaison George** was appointed as **CFO and Director** effective October 2023. * **Executive Remuneration:** The MD & Chairperson’s remuneration is fixed at **Rs. 2,00,000 per month** plus official car allowances. * **Internal Controls:** The company maintains a system of internal financial controls designed to safeguard assets. No material inefficiencies or significant regulatory orders impacting the company's status as a going concern were reported. ### Risk Profile and Market Challenges The company’s risk profile is heavily defined by its high geographic concentration and sensitivity to the regulatory and economic environment in **Sri Lanka**, which serves as its primary export market. * **Geopolitical and Economic Risk:** The ongoing **socio-economic crisis** in **Sri Lanka** has led to significant disruptions in revenue and cash flow. * **Payment and Liquidity Constraints:** Consignments frequently face non-timely payments, with collection cycles extending up to **6 months**. Due to the **Indian credit line facility** granted to **Sri Lanka**, the company has been forced to receive payments in **INR** instead of **USD**. * **Regulatory and Licensing Hurdles:** * Operations in **2025** were hampered by delays in the **license renewal process** in **Sri Lanka**. * The company abandoned the renewal of its **DCGI license** (expired **April 2022**) for importing **Human Recombinant Erythropoietin** due to a fee increase to **US$15,000 per strength**, which was deemed financially unfeasible. * **Supply Chain Challenges:** Business in the **Erythropoietin** segment declined significantly due to the inability to import from **China** post-pandemic and high **logistics costs** making imports uncompetitive against domestic Indian manufacturers. | Risk Category | Primary Impact | Status/Duration | | :--- | :--- | :--- | | **Geographic Concentration** | **Sri Lanka** (Prime export market) | High / Ongoing | | **Payment Cycle** | **6-month** delay per consignment | Persistent since **2023** | | **Regulatory Costs** | **US$15,000** per strength (DCGI fee) | License discontinued | | **Operational Capacity** | Underutilization due to **license renewal delays** | Reported **Aug 2025** |